Gerresheimer Faces Covenant Breach as Financial Reporting Deadline Missed

Gerresheimer faces a loan breach after missing its 2025 financial report deadline. BaFin expands its accounting probe, the company negotiates with lenders, and asset sales are planned amid a 72% stock plunge.

A failure to meet a key financial reporting deadline has triggered a technical breach of loan agreements at Gerresheimer. The packaging specialist missed the date for submitting its audited financial statements for 2025, an event that carries significant consequences beyond mere administrative delay.

Regulatory Scrutiny Intensifies Amid Widespread Accounting Issues

The German financial regulator, BaFin, has expanded its ongoing investigation into the company's accounts. Initially focused on irregularities concerning bill-and-hold sales, the probe now also encompasses lease liabilities totaling approximately €65.5 million and capitalized development costs of €29.4 million. For the 2025 fiscal year, the company anticipates impairment charges in the range of €220 to €240 million. These are primarily linked to technology projects at Sensile Medical AG and assets at the Chicago glass plant.

In response to the crisis, Gerresheimer is currently engaged in negotiations with its lenders to secure extensions on its credit facilities. The company now aims to publish the audited financial report in June 2026. Consequently, the release of its first-quarter results and its annual general meeting—originally scheduled for June 3—have been postponed indefinitely.

Strategic Asset Sales and Restructuring Underway

To bolster liquidity, management is actively pursuing the sale of its US subsidiary, Centor, with Morgan Stanley advising on the process. Concurrently, plans are in motion to shutter the Chicago Heights glass facility by the end of 2026, with production capacity relocating to sites in Italy and India.

Despite the current turmoil, Gerresheimer has provided financial guidance for 2026, projecting revenue between €2.3 and €2.4 billion and an adjusted EBITDA margin of 18% to 19%. However, the company explicitly states this outlook is contingent upon two critical factors: successful renegotiations with its creditors and a favorable conclusion to the BaFin investigation. This uncertainty leaves the capital market without a solid basis for valuation.

The equity has suffered dramatically, losing roughly 72% of its value over the past twelve months and currently trading near €19.25. The market is likely to remain in a holding pattern until June, when the audited accounts are finally presented and lenders announce their decisions, revealing whether the provided forecast is sustainable or must again be qualified.